Medical Cannabis

Germany to Soften Cannabis Insurance Reforms as Exilby Lobbying Row Escalates

Germany’s coalition government has retreated further on its controversial medical cannabis reimbursement reforms as it faces mounting questions over how and why the law came to be.

Germany Health Insurance Cannabis

Germany’s coalition government has retreated further on its controversial medical cannabis reimbursement reforms as it faces mounting questions over how and why the law came to be.

A swathe of clarification amendments, tabled last week and heading to the Bundestag Health Committee on Wednesday, would help soften some of the reforms’ most contested aspects, including the mandatory six-month finished medicine trial, which effectively funnelled patients towards Vertanical’s Exilby.

New revelations published as part of an investigation by Der Spiegel have now raised serious questions over how the Munich manufacturer’s new finished product gained such a privileged market position.

Germany’s federal health ministry has now formally denied any contact with Vertanical or its parent group Futrue over the emerging lobbying row.

Exilby’s entry into the GKV framework

The emerging issues centre around how and why the German state engineered such an unusual market shift inside a single twelve-month window.

To recap, on May 30, 2026, the federal drugs regulator (BfArM) approved Vertanical’s Exilby, a plant-derived cannabis extract, for chronic lower back pain with a neuropathic component.

Less than two months later, provisions were embedded in a broad health insurance savings package, the GKV-Beitragssatzstabilisierungsgesetz (BStabG), which passed through the Bundestag on July 10, taking effect on July 29, 2026.

This amendment, added late in the parliamentary process, cut dried cannabis flower out of statutory health insurance (GKV) altogether, stripping reimbursement from about 65,000 patients already using it.

Crucially, it also required doctors to place patients on a licensed cannabis-containing finished medicine for six months before they could prescribe a reimbursable extract. According to BfArM’s national survey of GKV cannabis prescriptions, 76.4% of patients cited chronic pain as their primary condition.

Just four cannabis products are licensed in Germany, and Exilby is the only one licensed for the treatment of pain.

In September, Exilby launched commercially, having cemented its position as the first-line reimbursable option for pain treatment. For any new pain patients, Exilby would effectively be compulsory for six months before any other cannabis treatment could be prescribed.

Why are there concerns surrounding it?

Last week, Der Spiegel published a follow-up to its August investigation, alleging that the Federal Ministry of Health (BMG) had met with representatives from Vertanical on June 21, 2024, organised by a lobbying firm. According to an email seen by the publication, this meeting was explicitly in relation to Exilby’s approval application, submitted on July 15, 2024.

Earlier reporting noted that Vertanical founder Clemens Fischer donated €560,000 across the four main centre parties before the February 2024 federal election, including €200,000 each to the CSU and FDP, €100,000 to the SPD and €60,000 to the CDU. The donations were legal and publicly disclosed, with Fischer stating that he wanted to ‘strengthen the political centre’.

More than a year later, in December 2025, Bavarian Minister-President Markus Söder visited Vertanical’s facility. At the time, according to Der Spiegel, BfArM president Karl Broich told colleagues he would need to answer questions on the state of the approval process in advance of the visit, and said the health ministry would also want to be kept informed.

Three months later, in March 2026, then-federal health minister Nina Warken (CDU) visited Fischer at Vertanical’s facility in Gräfelfing, outside Munich. The visit was documented by Vertanical itself, which posted a photo of the two online. Der Spiegel reports that in both cases, ministry officials asked BfArM for a status update on the approval before the visit.

The ministry’s own written answer to a parliamentary question by the Greens, published as a Bundestag paper on 23 September, confirms that Exilby was granted conditional approval, but must undergo a further efficacy study because of ‘remaining uncertainties regarding efficacy’.

Der Spiegel’s reporting cites internal memos from BfArM staff, noting not only that the Exilby decision rested on ‘the (oral) directive of management’, but that there were ‘considerable doubts about the benefit’ of the medicine during the approval process.

When asked about this in August, Vertanical pointed to two studies showing ‘significant pain reduction’. A follow-up request on the lobby contacts went unanswered.

On 22 June 2026, the then impartial chair of the Gemeinsamer Bundesausschuss (G-BA), the body that sets German reimbursement rules, Professor Josef Hecken, recommended the six-month finished-medicine trial that would soon become law at a Bundestag Health Committee hearing, specifically naming Exilby as a possible alternative. He resigned from the G-BA eight days later and was succeeded by Sonja Optendrenk on 1 July.

Asked by Greens health spokesperson Dr Paula Piechotta whether government officials had held ‘conversations or other contacts with representatives of Vertanical GmbH and/or FUTRUE GmbH’ during the approval process, the BMG said simply: ‘No’.

That denial covers neither the documented 21 June 2024 meeting nor Warken’s March 2026 visit. The ministry told Der Spiegel that such exchanges are ‘not unusual, especially for companies without approval experience’, and that because the formal application had not yet been filed, the June 2024 meeting did not fall within the ‘approval process’ the Greens had asked about.

The question of who authored the amendment inserted days before the bill’s passage also remains open, with conflicting accounts from government sources now in the public record.

The partial climbdown

Coalition parties have now tabled clarification amendments aimed at softening the six-month trial rule. If passed in Wednesday’s (October 7) health committee hearing, the trial would apply only where the patient’s condition is actually licensed under one of the four approved finished medicines.

Patients outside those indications, the majority of the German medical cannabis population, could then be prescribed reimbursable extracts immediately, and patients already stable on extracts could continue.

For the roughly 65,000 patients cut off from statutory cannabis flower reimbursement on July 29, the climbdown changes little. Patients with a life-threatening illness could, in theory, apply to their insurer to have flower covered as an emergency.

Apotheke Adhoc reported on 1 October that even that door has effectively closed. The pricing agreement between pharmacies and insurers that made the emergency route workable has now lapsed, leaving no agreed price for flower prescribed under it, and in practice, no reimbursement.

TopicsCannabis FlowerClemens FischerExilbygermanyGKVmedical cannabisReimbursementstatutory health insurance

Ben Stevens

Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.

More from Ben

Spotted an error, or have a tip? Contact the newsroom.

Up next · Medical Cannabis

More Tonnes, Tougher Economics: Europe’s Medical Cannabis Outlook for 2027

Oskar Fletcher · 18 November 2026

More